Skip to main content
Premium Trial:

Request an Annual Quote

Novosom, Isis Pharmaceuticals, Rosetta Genomics

Novosom Takes Option to License Isis Antisense Drugs
Novosom this week said it has acquired an exclusive six-month option to license antisense inhibitors targeting the CD40 membrane protein for all indications from Isis Pharmaceuticals.
“CD40 is a validated target for both inflammatory diseases and B-cell cancers,” Novosom said, adding that it would use the antisense drugs to target indications including Crohn's disease, transplants, rheumatoid arthritis, cancer, and multiple sclerosis.
The license will give Novosom rights to CD40, as well as oligonucleotides targeting CD40 and incorporating Isis' second-generation antisense chemistry. In exchange, Isis will receive an upfront exercise fee, milestone payments, and royalties.

Rosetta to Present Cancer Dx Development Data at AACR
Rosetta Genomics this week said it will present updated results on its lead diagnostics program for cancer of unknown primary origin at the annual meeting of the American Association for Cancer Research in Los Angeles later this month.
The data will be presented in a poster entitled, "MicroRNA Signature for Identification of Tumor Origin" by Nitzan Rosenfeld, team leader of computational biology at Rosetta.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.